AZEDRA was studied in the largest prospective
trial of patients with advanced pheochromocytoma
and paraganglioma

AZEDRA was studied in a Phase II, prospective, multicenter, open-label,
single-arm trial

patients received at least one
therapeutic dose
patients received two
therapeutic doses

Most patients were heavily pretreated and had received multiple types and lines of therapy

Metastatic Sites

Number of Prior
Treatment Modalities

Types of Prior
Treatment Modalities

Most Phase II trial AZEDRA® patients had disease in multiple locations.
Number of Prior Treatment Modalities.

Prior treatment modalities include surgery, radiation therapy, I-131 MIBG, and non-MIBG therapies.

Multiple types and lines of therapy.

Among patients treated with at least one dose of AZEDRA (N=68).

Help your patients find out if AZEDRA is right for them with a comprehensive guide

Download the AZEDRA
Patient Brochure

Learn about the proven efficacy of AZEDRA with actual patient cases from the pivotal Phase II trial